An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Completely surgically resected stage IIIb/c/d or stage IV melanoma within 12 weeks of
participation in study.

- Must have full activity or, if limited, must be able to walk and carry out activities
such as light house work or office work

- No prior anti-cancer treatment for melanoma (except surgery for the melanoma lesion(s)
and/or except for adjuvant radiation therapy (RT) after neurosurgical resection for
central nervous system (CNS) lesions)

Exclusion Criteria:

- History of uveal melanoma

- Patients with active, known or suspected autoimmune disease

- Prior treatment with interferon (if complete < 6 months prior to participation in
study), anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any
other antibody or drug specifically targeting T-cell co-stimulation or checkpoint
pathways

Other protocol defined inclusion/exclusion criteria could apply